title: Effects of a non thermal plasma treatment alone or in combination with gemcitabine in a MIA PaCa2-luc orthotopic pancreatic carcinoma model.
abstract: Pancreatic tumors are the gastrointestinal cancer with the worst prognosis in humans and with a survival rate of 5% at 5 years. Nowadays, no chemotherapy has demonstrated efficacy in terms of survival for this cancer. Previous study focused on the development of a new therapy by non thermal plasma showed significant effects on tumor growth for colorectal carcinoma and glioblastoma. To allow targeted treatment, a fibered plasma (Plasma Gun) was developed and its evaluation was performed on an orthotopic mouse model of human pancreatic carcinoma using a MIA PaCa2-luc bioluminescent cell line. The aim of this study was to characterize this pancreatic carcinoma model and to determine the effects of Plasma Gun alone or in combination with gemcitabine. During a 36 days period, quantitative BLI could be used to follow the tumor progression and we demonstrated that plasma gun induced an inhibition of MIA PaCa2-luc cells proliferation in vitro and in vivo and that this effect could be improved by association with gemcitabine possibly thanks to its radiosensitizing properties.
authors.affiliation: Centre d'Imagerie du Petit Animal-CIPA TAAM, UPS44 CNRS, Orléans, France. laura.brulle@cnrs-orleans.fr
authors.forename: Laura
authors.initials: L
authors.lastname: Brullé
authors.forename: Marc
authors.initials: M
authors.lastname: Vandamme
authors.forename: Delphine
authors.initials: D
authors.lastname: Riès
authors.forename: Eric
authors.initials: E
authors.lastname: Martel
authors.forename: Eric
authors.initials: E
authors.lastname: Robert
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Lerondel
authors.forename: Valérie
authors.initials: V
authors.lastname: Trichet
authors.forename: Serge
authors.initials: S
authors.lastname: Richard
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Pouvesle
authors.forename: Alain
authors.initials: A
authors.lastname: Le Pape
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D021441:Carcinoma, Pancreatic Ductal / Q000473:pathology / Q000628:therapy*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D058948:Cell Tracking; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D049409:Luciferases, Firefly / Q000096:biosynthesis; D051379:Mice; D010190:Pancreatic Neoplasms / Q000473:pathology / Q000628:therapy*; D058626:Plasma Gases / Q000627:therapeutic use*; D047368:Tumor Burden; D051598:Whole Body Imaging; D023041:Xenograft Model Antitumor Assays; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D058626:Plasma Gases; D003841:Deoxycytidine; D049409:Luciferases, Firefly; D000093542:Gemcitabine